Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
STAT3d
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal
Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...
Purdue University7mon
Purdue joins Lilly at LEAP in pharmaceutical training facility
INDIANAPOLIS — Purdue University is continuing its collaboration with Eli Lilly and Company as the Indianapolis-based pharmaceutical company’s official education partner at Indiana’s LEAP Research and ...
Fortune11mon
Eli Lilly
Founded over 145 years ago in Indianapolis, pharmaceutical company Eli Lilly established its first European affiliate in 1934. Lilly has provided more than two million doses of diabetes and cancer ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...